These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 25440595)
1. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists. Tang J; Li MP; Zhou HH; Chen XP Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595 [TBL] [Abstract][Full Text] [Related]
2. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. Tan GM; Lam YY; Yan BP Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998 [TBL] [Abstract][Full Text] [Related]
3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891 [TBL] [Abstract][Full Text] [Related]
4. Clinical effects and outcomes with new P2Y12 inhibitors in ACS. Collet JP; O'Connor S Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760 [TBL] [Abstract][Full Text] [Related]
5. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303 [TBL] [Abstract][Full Text] [Related]
6. A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs. Fayaz SM; Rajanikant GK Curr Pharm Des; 2012; 18(12):1625-34. PubMed ID: 22360514 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP; Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698 [TBL] [Abstract][Full Text] [Related]
8. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]. Cattaneo GJ; Podda GM; Cattaneo M Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491 [TBL] [Abstract][Full Text] [Related]
9. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104 [TBL] [Abstract][Full Text] [Related]
10. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412 [TBL] [Abstract][Full Text] [Related]
11. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415 [TBL] [Abstract][Full Text] [Related]
12. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036 [TBL] [Abstract][Full Text] [Related]
13. High and low on-treatment platelet reactivity to P2Y Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371 [TBL] [Abstract][Full Text] [Related]
14. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085 [TBL] [Abstract][Full Text] [Related]
15. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S Platelets; 2011; 22(7):504-15. PubMed ID: 21591981 [TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction? Moulias A; Xanthopoulou I; Alexopoulos D Curr Pharm Des; 2014; 20(28):4597-604. PubMed ID: 24730531 [TBL] [Abstract][Full Text] [Related]